Long-term, continuous dosing of etanercept in patients with plaque psoriasis

TY - JOUR

T1 - Long-term, continuous dosing of etanercept in patients with plaque psoriasis

AU - Papp, K.A.

AU - Krueger, G.G.

AU - Jemec, G.B.E.

AU - Van De Kerkhof, P.

AU - Robertson, D.

AU - Estojak, J.

AU - Pedersen, R.

AU - Foehl, J.

AU - Wajdula, J.

AU - Boggs, R.

AU - Molta, C.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Psoriasis, a chronic inflammatory skin disease, is characterized by periods of remission and relapse of lesions. Etanercept is approved for treatment of moderate-to-severe plaque psoriasis (25 mg twice weekly or 50 mg weekly). This review of three clinical trials evaluated the efficacy and safety of long-term, continuous (≥48 weeks) etanercept therapy in 1887 subjects with moderate-to-severe psoriasis (total exposure: 2458.0 subject-years). Efficacy end points across the three studies included: percent subjects achieving improvement of ;ge75% from baseline in the Psoriasis Area and Severity Index; mean percentage improvement from baseline of Psoriasis Area and Severity Index; mean Physician's Global Assessment psoriasis score; and Dermatology Life Quality Index total score (mean percentage improvement from baseline). Safety was also assessed. This article summarizes the sustained efficacy of long-term continuous etanercept therapy, which was generally consistent across the three trials. There were no new or unexpected safety signals with up to 144 weeks of continuous etanercept therapy. Long-term continuous etanercept therapy may be an option for some psoriasis patients.

AB - Psoriasis, a chronic inflammatory skin disease, is characterized by periods of remission and relapse of lesions. Etanercept is approved for treatment of moderate-to-severe plaque psoriasis (25 mg twice weekly or 50 mg weekly). This review of three clinical trials evaluated the efficacy and safety of long-term, continuous (≥48 weeks) etanercept therapy in 1887 subjects with moderate-to-severe psoriasis (total exposure: 2458.0 subject-years). Efficacy end points across the three studies included: percent subjects achieving improvement of ;ge75% from baseline in the Psoriasis Area and Severity Index; mean percentage improvement from baseline of Psoriasis Area and Severity Index; mean Physician's Global Assessment psoriasis score; and Dermatology Life Quality Index total score (mean percentage improvement from baseline). Safety was also assessed. This article summarizes the sustained efficacy of long-term continuous etanercept therapy, which was generally consistent across the three trials. There were no new or unexpected safety signals with up to 144 weeks of continuous etanercept therapy. Long-term continuous etanercept therapy may be an option for some psoriasis patients.

UR - http://www.scopus.com/inward/record.url?scp=79961091201&partnerID=8YFLogxK

U2 - 10.1586/edm.11.33

DO - 10.1586/edm.11.33

M3 - Journal article

AN - SCOPUS:79961091201

SN - 1746-9872

VL - 6

SP - 361

EP - 373

JO - Expert Review of Dermatology

JF - Expert Review of Dermatology

IS - 4

ER -